Advisors Capital Management LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 118,763 shares of the company’s stock after acquiring an additional 8,195 shares during the quarter. Johnson & Johnson makes up 1.1% of Advisors Capital Management LLC’s portfolio, making the stock its 22nd largest holding. Advisors Capital Management LLC’s holdings in Johnson & Johnson were worth $15,326,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of JNJ. Stuart Chaussee & Associates Inc. lifted its stake in shares of Johnson & Johnson by 20.7% during the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after buying an additional 80 shares in the last quarter. Selective Wealth Management purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at $105,000. CKW Financial Group lifted its stake in shares of Johnson & Johnson by 18.8% during the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock valued at $105,000 after buying an additional 128 shares in the last quarter. Mackey Komara & Dankovich LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $148,000. Finally, Ifrah Financial Services Inc. purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at $203,000. Institutional investors and hedge funds own 67.29% of the company’s stock.

Shares of JNJ stock opened at $136.52 on Tuesday. The firm has a market capitalization of $362.76 billion, a price-to-earnings ratio of 16.69, a P/E/G ratio of 2.07 and a beta of 0.68. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.20 and a current ratio of 1.47.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 EPS for the quarter, topping the consensus estimate of $1.95 by $0.02. The business had revenue of $20.39 billion for the quarter, compared to analysts’ expectations of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.74 EPS. As a group, equities analysts expect that Johnson & Johnson will post 8.58 earnings per share for the current fiscal year.

Johnson & Johnson announced that its board has authorized a share repurchase program on Monday, December 17th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 1.5% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

A number of research firms recently weighed in on JNJ. Zacks Investment Research restated a “sell” rating on shares of Johnson & Johnson in a research note on Monday, December 31st. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Barclays reiterated an “equal weight” rating and issued a $135.00 price target (down previously from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Wells Fargo & Co reiterated an “outperform” rating and issued a $152.00 price target (down previously from $162.00) on shares of Johnson & Johnson in a research note on Monday, January 14th. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a research note on Monday, February 25th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $143.58.

WARNING: “Advisors Capital Management LLC Has $15.33 Million Stake in Johnson & Johnson (JNJ)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2019/04/16/advisors-capital-management-llc-has-15-33-million-stake-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Total Return

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.